Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma

NCT ID: NCT06749600

Last Updated: 2025-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-14

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through clinical case reviews and newly identified cases. The study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study adopts a national, multicenter, observational design, incorporating both retrospective and prospective methodologies to collect and analyze primary ovarian leiomyosarcoma (POLMS) cases. The retrospective component will include cases diagnosed since 1980, leveraging institutional archives and clinical case reviews.

Data collection will be standardized using an electronic Case Report Form (eCRF) implemented on REDCap. All data will be centralized for uniformity and undergo rigorous validation to ensure consistency across centers. Findings will be reported in aggregated form to preserve patient confidentiality.

The study will gather extensive data points, including:

* Patient demographics.
* Clinical presentation and tumor characteristics (symptoms, tumor markers such as CA-125, CEA, and Ki-67).
* Treatment modalities (surgical details, lymphadenectomy, chemotherapy, radiotherapy, or hormonal therapy).
* Recurrence patterns and outcomes (disease-free survival, overall survival).
* Immunohistochemical findings (positivity for desmin, SMA, and vimentin). The statistical analysis primarily involves descriptive and exploratory techniques to identify patterns and correlations within the dataset.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Ovarian Leiomyosarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary leiomyosarcoma of the ovary (POLMS)

The study population includes patients aged between 18 and 99 years diagnosed with primary ovarian leiomyosarcoma (POLMS) afferent to participating centers. This population encompasses both historical cases diagnosed since 1980 and new cases identified during the study period.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of primary leiomyosarcoma of the ovary;
* Patients diagnosed with POLMS for whom data relating to diagnosis and treatment are available.
* Aged between 18 and 99 years

Exclusion Criteria

\- All patients with other forms of ovarian sarcoma (rhabdomyosarcomas, fibrosarcomas, stromal cell sarcomas) and patients diagnosed with leiomyosarcoma of the uterus will be excluded.
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Azienda USL Reggio Emilia - IRCCS

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AOU Policlinico di Modena

Modena, Italy, Italy

Site Status RECRUITING

Azienda Ospedaliero Universitaria di Parma - S.C. Ostetricia e Ginecologia

Parma, PR, Italy

Site Status RECRUITING

Azienda USL IRCCS di Reggio Emilia

Reggio Emilia, RE, Italy

Site Status RECRUITING

Malzoni - Avellino

Avellino, , Italy

Site Status RECRUITING

Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" - Catania

Catania, , Italy

Site Status RECRUITING

IRCCS Ospedale San Raffaele

Milan, , Italy

Site Status RECRUITING

Fondazione Irccs San Gerardo Dei Tintori

Monza, , Italy

Site Status RECRUITING

IRCCS Istituto Nazionale Tumori Fondazione Pascale

Napoli, , Italy

Site Status RECRUITING

Università degli Studi di Napoli Federico II

Napoli, , Italy

Site Status RECRUITING

Ospedale "Sacro Cuore"

Verona, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Vincenzo Dario Mandato, MD

Role: CONTACT

+39 0522 295467

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cinzia Baldessari, MD

Role: primary

Roberto Berretta, MD

Role: primary

+390521704068

Jasmine Lonetti, Clinical Research Coordinator

Role: primary

+39 0522295467

Francesca Falcone, MD

Role: primary

+39 0825 25596

Liliana Mereu, MD

Role: primary

+39 095 479 4111

Raffaella Cioffi, MD PhD

Role: primary

02 2643 4880

Tommaso Grassi, MD

Role: primary

Jole Ventriglia, MD

Role: primary

+39 081 17770468

Roberto Bianco, MD PhD

Role: primary

081-7462061

Giovanni Roviglione, MD

Role: primary

0456014581

References

Explore related publications, articles, or registry entries linked to this study.

Mandato VD, Torricelli F, Mastrofilippo V, Palicelli A, Costagliola L, Aguzzoli L. Primary Ovarian Leiomyosarcoma Is a Very Rare Entity: A Narrative Review of the Literature. Cancers (Basel). 2023 May 28;15(11):2953. doi: 10.3390/cancers15112953.

Reference Type BACKGROUND
PMID: 37296915 (View on PubMed)

Pu T, Fan L, Wang L, Li L, Zeng H. Recurrent primary ovarian leiomyosarcoma preconception, pregnancy, delivery, and puerperal management: A case report and literature review. J Obstet Gynaecol Res. 2022 Jun;48(6):1489-1494. doi: 10.1111/jog.15244. Epub 2022 Mar 30.

Reference Type BACKGROUND
PMID: 35354221 (View on PubMed)

Yuksel D, Cakir C, Kilic C, Karalok A, Kimyon G, Coteli S, Boyraz G, Tekin OM, Turan T. Primary leiomyosarcoma of the ovary: a report of three cases and a systematic review of literature. J Gynecol Obstet Hum Reprod. 2021 Jun;50(6):101825. doi: 10.1016/j.jogoh.2020.101825. Epub 2020 Jun 1.

Reference Type BACKGROUND
PMID: 32497729 (View on PubMed)

Pongsuvareeyakul T, Sukpan K, Chaicharoen S, Khunamornpong S. Leiomyosarcoma and Squamous Cell Carcinoma Arising in Mature Cystic Teratoma of the Ovary. Case Rep Pathol. 2017;2017:7907359. doi: 10.1155/2017/7907359. Epub 2017 Jul 2.

Reference Type BACKGROUND
PMID: 28751996 (View on PubMed)

He M, Deng YJ, Zhao DY, Zhang Y, Wu T. Synchronous leiomyosarcoma and fibroma in a single ovary: A case report and review of the literature. Oncol Lett. 2016 Apr;11(4):2510-2514. doi: 10.3892/ol.2016.4241. Epub 2016 Feb 17.

Reference Type BACKGROUND
PMID: 27073508 (View on PubMed)

Zygouris D, Androutsopoulos G, Grigoriadis C, Arnogiannaki N, Terzakis E. Primary ovarian leiomyosarcoma. Eur J Gynaecol Oncol. 2012;33(3):331-3.

Reference Type BACKGROUND
PMID: 22873115 (View on PubMed)

Chang A, Schuetze SM, Conrad EU 3rd, Swisshelm KL, Norwood TH, Rubin BP. So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity. Int J Surg Pathol. 2005 Apr;13(2):185-95. doi: 10.1177/106689690501300210.

Reference Type BACKGROUND
PMID: 15864383 (View on PubMed)

Nicotina PA, Antico F, Caruso C, Triolo O. Primary ovarian leiomyosarcoma. Proliferation rate and survival. Eur J Gynaecol Oncol. 2004;25(4):515-6.

Reference Type BACKGROUND
PMID: 15285319 (View on PubMed)

Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Mayerhofer-Gallenbacher N, Hudelist G, Czerwenka K. Immunohistochemical analysis of a primary ovarian leiomyosarcoma. Case report. Anticancer Res. 2003 Jul-Aug;23(4):3433-6.

Reference Type BACKGROUND
PMID: 12926085 (View on PubMed)

Seracchioli R, Colombo FM, Bagnoli A, Trengia V, Venturoli S. Primary ovarian leiomyosarcoma as a new component in the nevoid basal cell carcinoma syndrome: a case report. Am J Obstet Gynecol. 2003 Apr;188(4):1093-5. doi: 10.1067/mob.2003.86.

Reference Type BACKGROUND
PMID: 12712116 (View on PubMed)

Balaton A, Vaury P, Imbert MC, Mussy MA. Primary leiomyosarcoma of the ovary: a histological and immunocytochemical study. Gynecol Oncol. 1987 Sep;28(1):116-20. doi: 10.1016/s0090-8258(87)80016-1.

Reference Type BACKGROUND
PMID: 3308653 (View on PubMed)

Nogales FF, Ayala A, Ruiz-Avila I, Sirvent JJ. Myxoid leiomyosarcoma of the ovary: analysis of three cases. Hum Pathol. 1991 Dec;22(12):1268-73. doi: 10.1016/0046-8177(91)90110-b.

Reference Type BACKGROUND
PMID: 1748433 (View on PubMed)

Anderson B, Turner DA, Benda J. Ovarian sarcoma. Gynecol Oncol. 1987 Feb;26(2):183-92. doi: 10.1016/0090-8258(87)90272-1.

Reference Type BACKGROUND
PMID: 3643159 (View on PubMed)

Shakfeh SM, Woodruff JD. Primary ovarian sarcomas: report of 46 cases and review of the literature. Obstet Gynecol Surv. 1987 Jun;42(6):331-49. No abstract available.

Reference Type BACKGROUND
PMID: 3299172 (View on PubMed)

Azoury RS, Woodruff JD. Primary ovarian sarcomas. Report of 43 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol. 1971 Jun;37(6):920-41. No abstract available.

Reference Type BACKGROUND
PMID: 4378308 (View on PubMed)

Nieminen U, Numers CV, Purola E. Primary sarcoma of the ovary. Acta Obstet Gynecol Scand. 1969;48(3):423-32. doi: 10.3109/00016346909156657. No abstract available.

Reference Type BACKGROUND
PMID: 5370781 (View on PubMed)

KELLEY RR, SCULLY RE. Cancer developing in dermoid cysts of the ovary. A report of 8 cases, including a carcinoid and a leiomyosarcoma. Cancer. 1961 Sep-Oct;14:989-1000. doi: 10.1002/1097-0142(196109/10)14:53.0.co;2-u. No abstract available.

Reference Type BACKGROUND
PMID: 13752348 (View on PubMed)

Shafiee MN, Kah Teik C, Md Zain RR, Kampan N. Ovarian and uterine leiomyosarcoma: which one is the primary? Horm Mol Biol Clin Investig. 2019 Aug 9;41(2). doi: 10.1515/hmbci-2019-0037.

Reference Type BACKGROUND
PMID: 31398145 (View on PubMed)

Rampaul RS, Barrow S, Naraynsingh V. A primary ovarian leiomyosarcoma with micro-invasive features (stage I): is surgical excision enough? Gynecol Oncol. 1999 Jun;73(3):464; author reply 465-7. doi: 10.1006/gyno.1999.5384. No abstract available.

Reference Type BACKGROUND
PMID: 10366481 (View on PubMed)

Dixit S, Singhal S, Baboo HA, Vyas RK, Neema JP, Murthy R, Sooryanaraya U. Leiomyosarcoma of the ovary. J Postgrad Med. 1993 Jul-Sep;39(3):151-3.

Reference Type BACKGROUND
PMID: 8051647 (View on PubMed)

Inoue J, Gomibuchi H, Minoura S. A case of a primary ovarian leiomyosarcoma. J Obstet Gynaecol Res. 2000 Dec;26(6):401-7. doi: 10.1111/j.1447-0756.2000.tb01349.x.

Reference Type BACKGROUND
PMID: 11152324 (View on PubMed)

Walts AE, Lichtenstein I. Primary leiomyosarcoma associated with serous cystadenocarcinoma of the ovary. Gynecol Oncol. 1977 Mar;5(1):81-6. doi: 10.1016/0090-8258(77)90010-5. No abstract available.

Reference Type BACKGROUND
PMID: 858555 (View on PubMed)

Taskin S, Taskin EA, Uzum N, Ataoglu O, Ortac F. Primary ovarian leiomyosarcoma: a review of the clinical and immunohistochemical features of the rare tumor. Obstet Gynecol Surv. 2007 Jul;62(7):480-6. doi: 10.1097/01.ogx.0000268629.16151.71.

Reference Type BACKGROUND
PMID: 17572920 (View on PubMed)

Lastarria D, Sachdev RK, Babury RA, Yu HM, Nuovo GJ. Immunohistochemical analysis for desmin in normal and neoplastic ovarian stromal tissue. Arch Pathol Lab Med. 1990 May;114(5):502-5.

Reference Type BACKGROUND
PMID: 2159271 (View on PubMed)

Lerwill MF, Sung R, Oliva E, Prat J, Young RH. Smooth muscle tumors of the ovary: a clinicopathologic study of 54 cases emphasizing prognostic criteria, histologic variants, and differential diagnosis. Am J Surg Pathol. 2004 Nov;28(11):1436-51. doi: 10.1097/01.pas.0000141393.99300.d0.

Reference Type BACKGROUND
PMID: 15489647 (View on PubMed)

Bouie SM, Cracchiolo B, Heller D. Epithelioid leiomyosarcoma of the ovary. Gynecol Oncol. 2005 May;97(2):697-9. doi: 10.1016/j.ygyno.2005.02.008.

Reference Type BACKGROUND
PMID: 15863185 (View on PubMed)

Vijaya Kumar J, Khurana A, Kaur P, Chuahan AK, Singh S. A rare presentation of primary leiomyosarcoma of ovary in a young woman. Ecancermedicalscience. 2015 Apr 21;9:524. doi: 10.3332/ecancer.2015.524. eCollection 2015.

Reference Type BACKGROUND
PMID: 25932048 (View on PubMed)

Furutake Y, Fukagawa T, Suga Y, Nagasawa T, Sato S, Omi H, Kagabu M, Chiba A, Shoji T, Takeuchi S, Sugai T, Itamochi H, Sugiyama T. Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature. Int Cancer Conf J. 2017 Sep 11;7(1):11-15. doi: 10.1007/s13691-017-0309-7. eCollection 2018 Jan.

Reference Type BACKGROUND
PMID: 31149505 (View on PubMed)

Rasmussen CC, Skilling JS, Sorosky JI, Lager DJ, Buller RE. Stage IIIC ovarian leiomyosarcoma in a premenopausal woman with multiple recurrences: prolonged survival with surgical therapy. Gynecol Oncol. 1997 Sep;66(3):519-25. doi: 10.1006/gyno.1997.4824.

Reference Type BACKGROUND
PMID: 9299270 (View on PubMed)

Friedman HD, Mazur MT. Primary ovarian leiomyosarcoma. An immunohistochemical and ultrastructural study. Arch Pathol Lab Med. 1991 Sep;115(9):941-5.

Reference Type BACKGROUND
PMID: 1929791 (View on PubMed)

Cojocaru E, Palahepitiva Gamage G, Butler J, Barton DP, Thway K, Fisher C, Messiou C, Miah AB, Zaidi S, Gennatas S, Benson C, Huang P, Jones RL. Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit. Gynecol Oncol Rep. 2021 Mar 2;36:100737. doi: 10.1016/j.gore.2021.100737. eCollection 2021 May.

Reference Type BACKGROUND
PMID: 33732852 (View on PubMed)

Monk BJ, Nieberg R, Berek JS. Primary leiomyosarcoma of the ovary in a perimenarchal female. Gynecol Oncol. 1993 Mar;48(3):389-93. doi: 10.1006/gyno.1993.1067.

Reference Type BACKGROUND
PMID: 8462904 (View on PubMed)

Arslan OS, Sumer C, Cihangiroglu G, Kanat-Pektas M, Gungor T. A rare tumor of the female genital tract: primary ovarian leiomyosarcoma. Arch Gynecol Obstet. 2011 Mar;283 Suppl 1:83-5. doi: 10.1007/s00404-010-1735-3.

Reference Type BACKGROUND
PMID: 21061129 (View on PubMed)

Goodall EJ, Madhuri T, Manuel SB. The Management Dilemma of Leiomyosarcoma of the Ovary. World J Oncol. 2011 Oct;2(5):265-266. doi: 10.4021/wjon362w. Epub 2011 Oct 28.

Reference Type BACKGROUND
PMID: 29147259 (View on PubMed)

Pankaj, S., Choudhary, V., Singh, R. K., & Harsvardhan, R. (2013). High grade pleomorphic leiomyosarcoma of ovary in a young female: a case report. World Journal of Surgical Research, 2(3).

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

36/2024/OSS/AUSLRE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BR55 in Characterization of Ovarian Lesions
NCT03493464 TERMINATED PHASE2